Context: Despite considerable evidence that the economic and other benefits of asthma home visits far exceed their cost, few health care payers reimburse or provide coverage for these services.
Objective: To evaluate the cost and savings of the asthma intervention of a state-funded healthy homes program.
Design: Pre- versus postintervention comparisons of asthma outcomes for visits conducted during 2008-2012.
Setting: The New York State Healthy Neighborhoods Program operates in select communities with a higher burden of housing-related illness and associated risk factors.
Participants: One thousand households with 550 children and 731 adults with active asthma; 791 households with 448 children and 551 adults with asthma events in the previous year.
Intervention: The program provides home environmental assessments and low-cost interventions to address asthma trigger–promoting conditions and asthma self-management. Conditions are reassessed 3 to 6 months after the initial visit.
Main Outcome Measures: Program costs and estimated benefits from changes in asthma medication use, visits to the doctor for asthma, emergency department visits, and hospitalizations over a 12-month follow-up period.
Results: For the asthma event group, the per person savings for all medical encounters and medications filled was $1083 per in-home asthma visit, and the average cost of the visit was $302, for a benefit to program cost ratio of 3.58 and net benefit of $781 per asthma visit. For the active asthma group, per person savings was $613 per asthma visit, with a benefit to program cost ratio of 2.03 and net benefit of $311.
Conclusion: Low-intensity, home-based, environmental interventions for people with asthma decrease the cost of health care utilization. Greater reductions are realized when services are targeted toward people with more poorly controlled asthma. While low-intensity approaches may produce more modest benefits, they may also be more feasible to implement on a large scale. Health care payers, and public payers in particular, should consider expanding coverage, at least for patients with poorly controlled asthma or who may be at risk for poor asthma control, to include services that address triggers in the home environment.
New York State Health Department, Albany, New York (Ms Gomez); and National Center for Healthy Housing, Columbia, Maryland (Ms Reddy, Drs Dixon and Jacobs and Mr Wilson).
Correspondence: Amanda L. Reddy, MS, National Center for Healthy Housing, 10320 Little Patuxent Pkwy, Ste 500, Columbia, MD 21044 (firstname.lastname@example.org).
The authors thank the New York State Department of Health staff who administer the Healthy Neighborhoods Program and contributed to this work: Joan Bobier, Kenneth Boxley, Michael Cambridge, Thomas Carroll, Philip DiMura, and Lloyd Fox; the coordinators and staff at the county health departments; and the residents who welcomed them into their homes. The authors thank the staff of the Erie, Orange, Schenectady, and Clinton County Health Departments for their help in completing the time estimation study; Ruth Lindberg for assistance in designing the time estimation study; Trang Nguyen, Melissa Lurie, and Victoria Wagner of the New York State Department of Health for their assistance in acquiring and interpreting Medicaid data; and Tursynbek Nurmagambetov for his advice in designing a cost-benefit analysis.
The authors declare no conflicts of interest.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (http://www.JPHMP.com).
According to a 2014 survey, the vast majority of public and private health care payers do not provide or pay for home-based asthma services, with only 13 states reporting some Medicaid coverage and only 7 reporting that any private payers provide or reimburse home-based asthma services.1 However, numerous studies and systematic reviews have shown that home-based environmental interventions significantly reduce asthma morbidity and provide significant savings to our health care system and society.2–22 An economic analysis by the Community Preventive Services Task Force concluded that home-based, multitrigger, multicomponent interventions are a good investment, with each $1 invested yielding $5.30 to $14.00 in benefits (cost-benefit ratios of 5.3 and 14.0, respectively).23 Three recent studies yielded more modest ratios (ranging from 1.33 to 1.90).12,24,25 A study of 170 children with asthma who received an in-home intervention demonstrated reduced health care utilization and an annual net savings of about $821 304,11 and another study showed a net savings of $26 720 per 100 participants.13
The costs associated with asthma are large, estimated at $56 billion annually in 2007, suggesting that savings from effective interventions can also be large if implemented broadly.26 Although costs associated with lost days of school and work and premature death contribute to these totals, health care costs are the primary contributing factor. Annually, direct medical costs for the 22 million US children and adults with asthma are $1004 and $2077, respectively, more than those for children and adults without asthma.27,28
Control of housing and environmental factors is a key component of asthma control clinical guidelines but is often difficult to achieve within the clinical setting.29 Multiple studies and programs have reported that home-based asthma interventions produce a significant reduction in emergency department (ED) visits, hospitalizations, days with worsening asthma, days of school or work missed because of asthma, improvements in use of medications, use of asthma action plans, knowledge of personal asthma triggers, and how to avoid or reduce exposure to common triggers.21,30,31 Despite this evidence, these interventions have not been broadly implemented. This may be due, in part, to a lack of political will and inadequate collaboration between housing and health economic sectors,32 but concerns about the generalizability of the evidence base also present a barrier. For example, most previous studies have included several hundred subjects at most, are focused on children in low-income urban households, have short follow-up periods, or provide the same degree of intervention regardless of asthma severity.
The economic studies have had differing degrees of data quality and economic analysis, although at least 2 studies have rated economic asthma data to be between fair and good.23,33 Studies have produced economic results that vary with the frequency and number of home visits, type of professional staff, range of home improvement, and supplies provided. In addition, most economic studies on asthma have analyzed costs and benefits borne by society, including but not limited to those associated with the health sector. While this societal perspective is appropriate for public health professionals, there is also a need for studies that rely on a narrower payer perspective, focusing on the savings that accrue directly to the entity paying for the service (eg, a state Medicaid agency).
These gaps and variations in the evidence base may undermine confidence among health care payers that home-based interventions can be brought to scale successfully. This article aims to fill some knowledge gaps by using a payer perspective to examine economic costs and benefits associated with providing home-based asthma interventions on a large scale. The New York State (NYS) Healthy Neighborhoods Program (HNP)34 examined here addresses asthma as part of a comprehensive healthy homes approach. It is a useful model because of its scale (in 2015, it served almost 7000 homes, 18 000 adults and children, and 2400 individuals with asthma), reaches different types of housing, and has operated in 10 to 15 urban and rural counties. Using nonclinical staff, the interventions are tailored to the condition of the dwelling and the needs of its residents.
The NYS Department of Health (DOH) funds county health departments to provide in-home assessments and interventions to improve the environmental health and safety of residents in selected high-risk communities. Trained environmental health specialists (sanitarians, health educators, public health nurses, or other public health professionals) provide the intervention, which varies in scope according to the needs identified during the assessment and the expertise of the staff. To identify homes for an initial visit, the programs use door-to-door canvassing and referrals from other programs, organizations, or health care providers. Roughly a quarter of all households are revisited 3 to 6 months after the initial visit. Revisits are prioritized on households with a resident with asthma, but the timing and selection of households for revisit are determined by each program. We describe the program in detail in a separate article.35
During the initial visit, the surveyor visually identifies health and safety hazards and provides residents with guidance, products, and referrals to address the hazards. For example, if cockroaches are found, the surveyor may educate the family about reducing food and water sources, provide low-cost products (eg, gel baits or containers to store food and garbage), and make referrals to other services (eg, integrated pest management, professional cleaning). The surveyor also interviews each person with asthma or an adult proxy about asthma symptoms, health care utilization, and asthma management. A certified asthma educator may provide more detailed information and education than a sanitarian, but all surveyors can provide pamphlets and a blank asthma action plan, explain potential asthma triggers in the home and steps to reduce or eliminate exposure, distribute low-cost products to address triggers, provide referrals to services, reinforce basic self-management messages, and share information about the New York Health Insurance Exchange.
Thirteen counties were funded during 2008-2012 and 10 continuously. The staff conducted asthma assessments for 8813 residents who had been told by a health care professional that they had asthma. Of these, 2284 (26%) were revisited. We excluded 273 children 0 to 4 years old (asthma is difficult to diagnose in this age group) and 10 children missing age, leaving 2001 persons. To compare the impact of targeting the intervention with residents with more poorly controlled asthma, we created 2 groups: the asthma events group (representing individuals with more poorly controlled asthma) and the active asthma group. We defined asthma events as an asthma attack in the past 3 months and/or 1 or more medical encounters in the past 12 months for an asthma attack or worsening symptoms, including an ED or urgent care visit, health care professional visit, and/or a hospital stay. Individuals reporting 1 or more of these events at the initial visit were assigned to the asthma events group (n = 1616). The active asthma group (n = 1963) includes the asthma events group plus individuals who did not have any medical encounters but reported use of either a quick relief (QR) medication or a controller medication. This corresponds most closely to the Centers for Disease Control and Prevention's definition of active asthma.36 Finally, to minimize re-reporting of events resulting from a large overlap in the 12-month recall period and the correlation between the benefit and interval, we selected individuals with the revisit 91 to 365 days after the initial visit, giving 1281 persons in the active asthma group and 999 in the asthma events group. The program evaluation of the HNP was reviewed by the institutional review board of the NYS DOH and given exempt status on the basis of not being research.
Program cost estimates
The HNP provides a framework of core operating procedures that are consistent across all of the county programs; however, the counties are encouraged to build on local resources and infrastructure to deliver services that are meaningful and effective for each community. These variations result in a range of costs of providing the asthma intervention. We conducted a cost estimation study to estimate the average cost of an HNP visit. Costs include salaries and fringe benefits for staff (whether paid or not by state funding), travel, and products. The study was conducted in 4 counties that are representative of the scope, geography, and administration of the program. We worked with each county to develop a daily time record worksheet for each job title (eg, public health educator, supervisor, administrator). Each worksheet included the following activities: time spent on visits, travel, office work (eg, processing paperwork, preparing budgets and reports, purchases), community outreach, staff meetings, and products and materials. Each county selected two 2-week study periods (10 business days), one each in the spring and fall, when staffing was at a maximum and activities would be typical. The staff were trained in advance of the data collection. The NYS DOH staff reviewed the worksheets for completeness and gathered salary information and typical costs associated with travel and products provided. Products and educational materials obtained at no cost were not included in the overall cost of the program.
The cost per asthma visit was the sum of 6 expenditure categories:
1. Cost of the standard healthy homes visit: total salary cost of general activities and travel (minutes × salary per minute) conducted by the field staff divided by the total number of home visits.
2. Additional cost of asthma visits: salary cost of time spent conducting the asthma visit (minutes × salary per minute) divided by the number of homes where at least 1 resident with asthma was evaluated.
3. Administrative costs of a home visit: salary cost of the administrative staff divided by the total number of visits conducted by the field staff.
4. Cost of travel: the number of miles traveled multiplied by travel reimbursement, divided by the total number of visits. (Asthma visits were not calculated separately because home visits and asthma visits are often conducted on a single trip.)
5. Cost of standard products provided at all home visits: total cost of purchasing products divided by the total number of home visits.
6. Cost of asthma-specific products: total cost of purchasing products divided by the number of asthma visits.
The final estimated cost per asthma visit is the sum of the 6 expenditure categories.
During HNP visits, assessment, and intervention, information is collected using a standardized asthma assessment form (see documents, Supplemental Digital Content 1, available at: http://links.lww.com/JPHMP/A289). For this analysis, we used the following self-reported data on medical encounters and medication use:
1. Number of visits to a doctor or other health care professional for worsening asthma or an asthma attack in the past 12 months.
2. Number of visits to an ED or urgent care center because of asthma in the past 12 months.
3. Number of overnight stays in the hospital because of asthma in the past 12 months.
4. Has a prescription for QR medicine and, if yes, the number of times QR medicine was used in the past week.
5. Has a prescription for daily controller medicine and, if yes, took it every day in the past week.
For medical encounters (points 1-3), the change in encounters is the number reported by an individual at the initial visit (preintervention) minus the number reported at the revisit (postintervention). Because the recall period (12 months) was longer than the interval between the initial visit and revisit, we calculated an annualized change that takes into account the time between the visits (see Document, Supplemental Digital Content 1, available at: http://links.lww.com/JPHMP/A289). We assumed one uniform distribution for encounters during the 12 months before the initial visit and another for encounters during the 12 months after the initial visit. To minimize the effects of outliers, values below the 1st percentile and above the 99th percentile were replaced by the values at the 1st and 99th percentiles, respectively (Winsorization). For medication use (points 4 and 5), we identified the group of residents with asthma who had a prescription for a QR medication, at either the initial or the revisit, and the group that had a controller medication at either visit. The change is the proportion that reported using a QR medication in the past week at the initial visit minus the proportion at the revisit. For controller medications, the change is the proportion that had used the controller every day in the past week at the initial visit minus the proportion at the revisit.
The NYS Office of Health Insurance Programs provided the authors with the total cost in 2010 for asthma-related services and medications filled for Medicaid enrollees covered by managed care organizations. The average cost per person receiving the service was $265 for outpatient visits, $250 for ED visits, and $8667 for hospital stays. For medications, the average cost per enrollee (whether or not a person filled a prescription) was $145 for QR medications and $980 for controller medications. The benefit in dollars is the mean change in the medical encounter or medication use multiplied by the average cost of the medical encounter or prescription.
The benefit to cost ratio is the benefit (the change in the health care utilization) divided by the cost of an HNP asthma visit. A ratio greater than 1.0 represents the proportion of savings (averted expenditures) after the HNP asthma intervention. We calculated the ratio for all medical encounters and medications combined, as well as for each medical encounter and medication, for medical encounters combined, and for medication use combined.
Because the asthma events group is a subset of the active asthma group, the following summary is for the asthma events group (Table 1). The primary respondents were 57% white (similar to 2 programs in urban areas and much lower than the 2 rural and semirural counties), 69% of households received some public assistance, and 41% of adults were smokers. Sixty-nine percent of dwellings were built before 1950 and another 20% were built between 1950 and 1978.
Tables 2 and 3 present summary statistics for the number of medical encounters and medication use, respectively. The following summary is for the asthma events group. Persons in the asthma events group reported significant reductions in the number of visits to health care professionals, ED/urgent care, and hospital stays. At the initial visit, the mean number of visits to a health care professional was 2.6 per year and 2.0 per year at the revisit, with a mean decrease of 1.6 per year (P < .001). For visits to an ED or urgent care, the mean number went from 0.7 per year to 0.6 per year, a mean decrease of 0.5 per year (P < .001), and for hospital stays, the mean decrease was 0.1 per year (P = .003).
Ninety-four percent of persons in each asthma group reported having a prescription for a QR medication at one or both visits (Table 3). In the asthma events group, 58% reported using their QR medication at least once in the past week and 48% at the revisit. For controller medications, at the initial visit, 83% of persons in the asthma events group reported taking their medication every day in the past week and 83% at the revisit in the active asthma group.
Table 4 presents the benefit and cost analysis. The highest average cost of an asthma visit among the 4 estimates was $302. For the 4 counties combined, the average percentage that each expenditure category contributed to the cost of an asthma visit was 13% for the cost of labor of an asthma assessment and intervention; 3% for mileage to and from an asthma visit; 27% for products provided at an asthma visit; 34% for administrative costs (including the cost of administrative and office activities and office supplies); and 23% for fringe benefits (data not shown). The average cost of health care utilization in 2010 was $97 for a visit to a health care professional, $180 per ED visit, $6866 per hospital stay, $145 for QR medications, and $980 for controller medications. For the asthma events group, the highest benefit in dollars (ie, cost savings) was $824 per hospital stay, followed by $156 for visits to a health care professional, $88 for ED visits, and $15 for medications, for a total savings of $1083 per asthma visit. This gives a benefit to cost ratio of 3.58 and an average net savings of $781 ($1083 − $302). For the active asthma group, the benefit was $613, the benefit to cost ratio was 2.03, and the net savings was $311.
This analysis confirms that the economic benefits of home-based environmental asthma interventions outweigh the costs. It adds evidence for the impact on previously understudied populations, including adults with asthma and rural communities. It also underscores the potential for increased benefits when services are targeted to residents with poorly controlled asthma. Most importantly, benefits are realized even when the intervention is deployed on a large scale, using nonclinical staff and when a narrow, public payer perspective is used for calculating potential benefits.
Like previous studies,23 some health care costs (notably prescription medications) increased after the intervention. The benefits indicate that health care savings were largely driven by the decrease in hospitalizations. The benefits realized by the NYS HNP were more modest than those reported by the Community Guide to Preventive Services: $5 to $14 returned for every $1 invested compared with our findings of $2.03 to $3.58 benefit for every $1 invested. It is possible that, while we focused exclusively on health care utilization, other studies relied on a societal perspective that monetizes social benefits, such as missed school days or symptom-free days. Compared with more recent studies,12,24,25 both the asthma events group and the active asthma group had a slightly greater benefit to program cost ratios. This may be due to differences in the populations served and program design. The cost of the HNP's low-intensity, single-visit approach is very modest. Many programs provide the intervention over multiple visits, conduct follow-up visits for all participants, and provide more intense services (eg, professional cleaning, integrated pest management) and remediation (eg, carpet removal, repair of leaks). These differences in program design can increase costs as well as the magnitude of the benefits. That is, a payer seeking to implement a program that provides a follow-up visit to all participants may see not only a slight increase in costs but also a slight increase in benefits associated with the extra opportunity to reinforce environmental messages. More importantly, a payer need not rely on externalized social benefits (eg, lost school days) to realize a significant financial improvement in the bottom line for asthma care.
Strengths and limitations
This evaluation is important and unique, particularly due to its large sample size, geographically diverse population, inclusion of adults with asthma, use of nonclinical staff, and use of a payer perspective. The payer perspective estimates the benefits that apply to investors from the health care sector. The evaluation also provides support for taking asthma home-based services to scale in real-world settings in order to reduce medical costs borne by health care payers.
The relatively short follow-up period prevents an examination of long-term sustainability of benefits. Conversely, the low-intensity approach and the short follow-up period are likely more relevant for services offered at scale through the health care sector. The overlap in recall period for key asthma outcomes posed a challenge for pre- and postintervention comparisons, but we attempted to correct for the overlap. Another important limitation is the lack of a comparison group, which precludes attributing the entirety of the observed improvements to the intervention. However, the analysis compared impacts across groups of patients and showed the expected increase in benefits for patients with more poorly controlled asthma.
Because of the flexible protocol, there are differences in the way that the programs or staff assess homes and conduct interventions. While this is advantageous for providing services that address a range of challenges faced by residents in HNP communities (including housing conditions, occupant behaviors/attitudes, available resources), our findings may not be representative of communities elsewhere. In addition, aggregating findings across the counties may mask geographic variation in housing conditions, improvements, and operating costs. Therefore, to avoid overestimating the potential benefits, we used the highest cost per asthma visit among the 4 programs that participated in the time estimation study. This conservative approach was also important because the program costs reported do not include supplies or services that were obtained at no cost or provided by the resident or property owner (eg, costs of repairs or ongoing pest management). Similar services offered through the health care sector may incur different costs due to differences in staffing, program design, age and quality of housing stock, or ability to obtain products and services at low or no cost. At the same time, the use of Medicaid-managed care costs to estimate health care utilization spending and savings may underestimate the potential benefit of the intervention. This analysis suggests that avoided hospitalizations may be a large driver of savings on a population level, and in 2011, NYS reported that among all sources of payment, Medicare had the highest average cost of $25 227 for asthma hospitalizations, followed by other third party or private insurance ($16 725), Medicaid ($14 633), and self-pay ($11 382). While a majority of households reported being eligible for public assistance, and therefore are likely to be eligible for Medicaid in NYS, the analysis was not adjusted to reflect the higher cost of other potential payment sources. Finally, the benefits of this intervention are likely underestimated, as the intervention (and associated costs) addresses a range of health and safety hazards in the home, but only improvements in asthma outcomes were monetized. The actual cost to benefit ratio may be much higher.
Sources of bias include selection bias (which homes allow access and which are targeted for revisit), recall bias (resident reporting of exposure to triggers following an ED visit), social desirability bias (residents may not be forthcoming about issues such as tobacco use or presence of cockroaches), and reporting bias (surveyors' subjectivity in evaluating their own work at the revisit). However, having a different surveyor at the revisit did not change the outcomes (data not shown) and the impact of social desirability bias is mitigated by a reliance on visual assessment (eg, the presence of ashtrays outweighs a statement that no smoking occurs in the home). Finally, there were significant reductions in the Winsorized annualized number of visits to health care professionals, ED/urgent care, and hospital stays for both groups. Although Winsorizing is a robust method of lessening the effects of outliers, it dampens the effects of extremely high and low changes on the means.
Low-intensity, home-based, environmental interventions for people with asthma decrease the cost of health care utilization, and greater reductions are realized when services are targeted toward people with more poorly controlled asthma. Benefits can be realized for both children and adults with asthma, in urban and rural settings, and when using a narrow payer perspective that does not include societal benefits. Availability of a workforce capable of conducting a visual assessment and providing an environmental intervention is often perceived as a barrier to large-scale implementation and as such this program's reliance on nonclinical staff and a low-intensity approach is notable. While this approach may produce benefits that are more modest than higher-intensity approaches, it may also be more feasible to implement on a large scale and in a variety of communities. Future evaluations should focus on collecting more detailed data on asthma outcomes and program costs and articulating the impact of differences in program design, intensity, and scale on health care utilization and program costs.
Implications for Policy & Practice
* For health care payers, and public payers in particular, this article adds to the evidence base that home-based environmental interventions can shift costs from treating worsening asthma to controlling it and reduce overall health care utilization costs.
* Payers should consider expanding coverage, at least for patients with poorly controlled asthma or who may be at risk for poor asthma control, to include services that address triggers in the home environment.
1. National Center for Healthy Housing. Healthcare Financing of Healthy Homes: Findings From a 2014 Nationwide Survey of State Reimbursement Policies. Columbia, MD: National Center for Healthy Housing. http://http://www.nchh.org
/Resources/HealthcareFinancing/Snapshot.aspx. Accessed 2015.
2. Krieger J, Takaro TK, Song L, Beaudet N, Edwards K. A randomized controlled trial of asthma self-management support comparing clinic-based nurses and in-home community health workers: the Seattle-King County Healthy Homes II Project. Arch Pediatr Adolesc Med. 2009;163(2):141–149.
3. Krieger JW, Takaro TK, Song L, Weaver M. The Seattle-King County Healthy Homes Project: a randomized, controlled trial of a community health worker intervention to decrease exposure to indoor asthma triggers. Am J Public Health. 2005;95(4):652–659.
4. Dixon SL, Fowler C, Harris J, et al An examination of interventions to reduce respiratory health and injury hazards in homes of low-income families. Environ Res. 2009;109(1):123–130.
5. Krieger JW, Philby ML, Brooks MZ. Better home visits for asthma lessons learned from the Seattle-King County Asthma Program. Am J Prev Med. 2011;41(2)(suppl 1):S48–S51.
6. Wilce MA, Garbe PL. Evaluating home-based, multicomponent, multi-trigger interventions: your results may vary. Am J Prev Med. 2011;41(2)(suppl 1):S52–S54.
7. Breysse J, Wendt J, Dixon S, et al Nurse case management and housing interventions reduce allergen exposures: the Milwaukee randomized controlled trial. Public Health Rep. 2011;126(suppl 1):S89–S99.
8. Bryant-Stephens T, Li Y. Outcomes of a home-based environmental remediation for urban children with asthma. J Natl Med Assoc. 2008;100(3):306–316.
9. Barnes CS, Amado M, Portnoy JM. Reduced clinic, emergency room, and hospital utilization after home environmental assessment and case management. Allergy Asthma Proc. 2010;31(4):317–323.
10. Morgan WJ, Crain EF, Gruchalla RS, et al Results of a home-based environmental intervention among urban children with asthma. N Engl J Med. 2004;351(11):1068–1080.
11. Turcotte DA, Alker H, Chaves E, Gore R, Woskie S. Healthy homes: in-home environmental asthma intervention in a diverse urban community. J Public Health. 2014;104(4):665–671.
12. Woods ER, Bhaumik U, Sommer SJ, et al Community asthma initiative: evaluation of a quality improvement program for comprehensive asthma care. Pediatrics. 2012;129(3):465–472.
13. Nguyen KH, Boulay E, Peng J. Quality-of-life and cost-benefit analysis of a home environmental assessment program in Connecticut. J Asthma. 2011;48(2):147–155.
14. Parker EA, Israel BA, Robins TG, et al Evaluation of community action against asthma: a community health worker intervention to improve children's asthma-related health by reducing household environmental triggers for asthma. Health Educ Behav. 2008;35(3):376–395.
15. Carter MC, Perzanowski MS, Raymond A, Platts-Mills TA. Home intervention in the treatment of asthma among inner city children. J Allergy Clin Immunol. 2001;108(5):732–737.
16. Eggleston PA, Butz A, Rand C, et al Home environmental intervention in inner-city asthma: a randomized controlled clinical trial. Ann Allergy Asthma Immunol. 2005;95(6):518–524.
17. Levy JI, Brugge D, Peters JL, Clougherty JE, Saddler SS. A community-based participatory research study of multifaceted in-home environmental interventions for pediatric asthmatics in public housing. Soc Sci Med. 2006;63(8):2191–2203.
18. Turyk M, Banda E, Chisum G, et al A multifaceted community-based asthma intervention in Chicago: effects of trigger reduction and self-management education on asthma morbidity. J Asthma. 2013;50(7):729–736.
19. Crocker DD, Kinyota S, Dumitru GG, et al Effectiveness of home-based, multi-trigger, multicomponent interventions with an environmental focus for reducing asthma morbidity: a community guide systematic review. Am J Prev Med. 2011;41(2)(suppl 1):S5–S32.
20. Postma J, Karr C, Kieckhefer G. Community health workers and environmental interventions for children with asthma: a systematic review. J Asthma. 2009;46(6):564–576.
21. Krieger J, Jacobs DE, Ashley PJ, et al Housing interventions and control of asthma-related indoor biologic agents: a review of the evidence. J Public Health Manag Pract. 2010;16(5)(suppl):S11–S20.
22. Welsh EJ, Hasan M, Li P. Home-based educational interventions for children with asthma. Cochrane Database Syst Rev. 2011;(10):CD008469.
23. Nurmagambetov TA, Barnett SB, Jacob V, et al Economic value of home-based, multi-trigger, multicomponent interventions with an environmental focus for reducing asthma morbidity—a Community Guide systematic review. Am J Prev Med. 2011;41(2)(suppl 1):S33–S47.
24. Campbell JD, Brooks M, Hosokawa P, Robinson J, Song L, Krieger J. Community health worker home visits for Medicaid-enrolled children with asthma: effects on asthma outcomes and costs. Am J Public Health. 2015;105(11):2366–2372.
25. Bhaumik U, Norris K, Charron G, et al A cost analysis for a community-based case management intervention program for pediatric asthma. J Asthma. 2013;50(3):310–317.
26. Centers for Disease Control and Prevention. Asthma Statistics: United States. Milwaukee, WI: American Academy of Allergy Asthma and Immunology. http://http://www.aaaai.org
/about-aaaai/newsroom/asthma-statistics. Published 2011. Accessed 2015.
27. Centers for Disease Control and Prevention. Asthma: National Data: National Current Asthma Prevalence. Atlanta, GA: Centers for Disease Control and Prevention; 2013. http://http://www.cdc.gov
/asthma/most_recent_data.htm. Published 2013. Updated October 2015. Accessed 2016.
28. Kamble S, Bharmal M. Incremental direct expenditure of treating asthma in the United States. J Asthma. 2009;46(1):73–80.
29. National Heart, Lung, and Blood Institute and National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma—Full Report 2007. Bethesda, MD: NHLBI Health Information Center; 2007. http://http://www.nhlbi.nih.gov
/health-pro/guidelines/current/asthma-guidelines/full-report. Accessed 2015.
30. National Center for Healthy Housing. Case Studies: The Benefits of Home Asthma Visits for Children With Asthma. Columbia, MD: National Center for Healthy Housing. http://http://www.nchh.org
/Portals/0/Contents/Asthma-Home-Visits–Case-Studies_%20July-2014.pdf. Published 2014. Accessed 2015.
31. Krieger J, Jacobs DE. Healthy housing. In: Dannenberg AL, Frumkin H, Jackson RL, eds. Making Healthy Places: Designing and Building for Health, Well-being, and Sustainability. Washington, DC: Island Press; 2011;170–187.
32. Jacobs DE, Kelly T, Sobolweski J. Linking public health, housing, and indoor environmental policy: successes and challenges at local and federal agencies in the United States. Environ Health Perspect. 2007;115(6):976–982.
33. Yong YV, Shafie AA. Economic evaluation of enhanced asthma management: a systematic review. Pharm Pract. 2014;12(4):493.
34. New York State Department of Health. Healthy Neighborhoods Program. Albany, NY: New York State Department of Health. https://http://www.health.ny.gov
/environmental/indoors/healthy_neighborhoods. Updated 2014. Accessed 2015.
35. Reddy A, Gomez M, Dixon SL. The New York State Healthy Neighborhoods Program: findings from an evaluation of a large-scale, multi-site, state-funded healthy homes program. J Public Health Manag Pract. 2017;23(2):210–218.
36. Centers for Disease Control and Prevention. Frequent Use of Quick-Relief Medication Among Persons With Active Asthma. Atlanta, GA: Centers for Disease Control and Prevention. http://http://www.cdc.gov
/asthma/asthma_stats/overuse.htm. Updated 2015. Accessed 2016.
asthma; asthma intervention; cost-benefit analysis; economics; healthy homes; healthy housing; housing
Supplemental Digital Content
Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.